Two-year data from the TOBA II BTK clinical trial demonstrate durability of dissection repair below the knee with the Philips Tack Endovascular System
03 juin 2021 14h40 HE | Royal Philips
June 3, 2021 Results show that first-of-its-kind device has a sustained treatment effect and a positive impact on quality of life Amsterdam, the Netherlands – Royal Philips (NYSE: PHG,...
Cynata-logo.png
UK Regulatory Authority Approves Cynata’s Phase 2 Clinical Trial in Critical Limb Ischaemia
14 janv. 2020 08h05 HE | Cynata Therapeutics Limited
MELBOURNE, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has...
Cynata-logo.png
Cynata Receives Favourable Advice from UK MHRA on CLI Clinical Trial
12 mars 2019 09h03 HE | Cynata Therapeutics Limited
MELBOURNE, Australia, March 12, 2019 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that...
hemostemix-logo-small.jpg
Hemostemix Announces UC Davis Health Added as a Trial Site for Phase II Clinical Trial
25 févr. 2019 08h30 HE | Hemostemix Inc.
CALGARY, Alberta, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from UC...
hemostemix-logo-small.jpg
Hemostemix Announces Submission of Orphan Drug Designation Application to the FDA
04 févr. 2019 08h30 HE | Hemostemix Inc.
CALGARY, Alberta, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) a biotechnology company focused on developing and commercializing...
hemostemix-logo-small.jpg
Hemostemix Announces Two Additional Sites Enrolled in Phase II Clinical Trial
03 janv. 2019 08h00 HE | Hemostemix Inc.
CALGARY, Alberta, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from two...
hemostemix-logo-small.jpg
Hemostemix Announces Development of an ACP-01 Allogeneic Process and Initiation of R&D for Autologous NCP-01 Neural Cellular Precursors
09 nov. 2018 08h30 HE | Hemostemix Inc.
CALGARY, Alberta, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to provide the following update on its research and...
hemostemix-logo-small.jpg
Hemostemix Announces Important Manufacturing Process Refinements
08 nov. 2018 08h30 HE | Hemostemix Inc.
CALGARY, Alberta, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that is has completed refinements to its...
Endonovo Reports Positive Results in Critical Limb Ischemia Study Using Non-Invasive Medical Device
12 févr. 2018 09h32 HE | Endonovo Therapeutics, Inc.
LOS ANGELES, CA, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive wearable Electroceutical™...
New Proteon Logo - full color RGB.jpg
Proteon Therapeutics Announces First Patient Dosed in Phase 1 Study Evaluating Vonapanitase for the Treatment of Peripheral Artery Disease Below the Knee
10 nov. 2016 08h00 HE | Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...